Divya Kolli
Medical · Yuba City, CANPI 1811340391
Payments from drug & device makers
Across 138 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Bayer$253
- Johnson & Johnson$155
- Novo Nordisk$126
- Daiichi Sankyo Inc.$99
- Pfizer$98
- plus $530 from 16 others
What the payments were for
- Food & beverage$2,550100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 75 | $1,290 |
| Bayer | 13 | $253 |
| Johnson & Johnson | 7 | $155 |
| Novo Nordisk | 7 | $126 |
| Daiichi Sankyo Inc. | 5 | $99 |
| Pfizer | 4 | $98 |
| Dexcom, Inc. | 3 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $83 |
| Exact Sciences | 4 | $66 |
| Alk-abello, Inc | 3 | $52 |
| GSK | 2 | $32 |
| Viiv Healthcare Company | 1 | $31 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Lilly USA, LLC | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Merck | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Cranial Technologies, Inc | 1 | $13 |
How this compares
$2,550 in reported general payments places this provider in the 75th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 50 | $45,768 |
| JanuviaSitagliptin Phosphate | 52 | $40,009 |
| KerendiaFinerenone | 24 | $29,184 |
| FarxigaDapagliflozin Propanediol | 17 | $24,324 |
| JanumetSitagliptin Phos/Metformin Hcl | 34 | $21,122 |
| JardianceEmpagliflozin | 34 | $20,804 |
| TradjentaLinagliptin | 23 | $17,742 |
| RybelsusSemaglutide | 13 | $15,730 |
| EntrestoSacubitril/Valsartan | 25 | $15,648 |
| SynjardyEmpagliflozin/Metformin Hcl | 16 | $13,455 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $9,067 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $7,933 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $7,929 |
| Spiriva HandihalerTiotropium Bromide | 12 | $6,184 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $6,009 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $126 | $61,49963 claims |
| MerckJanuvia, Janumet | $17 | $61,13286 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $18 | $52,00173 claims |
| BayerKerendia | $253 | $29,18424 claims |
| AstraZenecaFarxiga | $17 | $24,32417 claims |
| GSKAnoro Ellipta, Breo Ellipta, Shingrix | $32 | $17,45747 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,087 medical providers in California.
Other medical in Yuba City
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- Deirdre MoxleyFullerton$149K
- Tri leGardena$127K
- Linda RankLadera Ranch$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.